Visionary Wealth Advisors Purchases New Position in Halozyme Therapeutics, Inc. $HALO

Visionary Wealth Advisors purchased a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 5,195 shares of the biopharmaceutical company’s stock, valued at approximately $407,000.

Several other large investors also recently added to or reduced their stakes in HALO. Measured Wealth Private Client Group LLC lifted its stake in shares of Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 124 shares during the last quarter. Larson Financial Group LLC boosted its holdings in shares of Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 343 shares during the period. MidFirst Bank bought a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at approximately $27,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Halozyme Therapeutics during the 2nd quarter valued at $28,000. Finally, Quantbot Technologies LP purchased a new stake in Halozyme Therapeutics during the 2nd quarter valued at $30,000. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Price Performance

HALO opened at $108.64 on Tuesday. The business has a fifty day moving average of $83.94 and a 200 day moving average of $73.96. Halozyme Therapeutics, Inc. has a 52-week low of $61.22 and a 52-week high of $109.10. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The stock has a market cap of $12.33 billion, a P/E ratio of 32.43, a PEG ratio of 0.43 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The business had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. During the same quarter last year, the firm posted $1.54 earnings per share. The business’s revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current year.

Insider Transactions at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 1,626 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the transaction, the director directly owned 40,418 shares in the company, valued at approximately $4,154,970.40. This represents a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the transaction, the director directly owned 14,462 shares in the company, valued at $1,084,650. This represents a 33.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 64,103 shares of company stock worth $5,226,496. Insiders own 2.50% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on HALO. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. UBS Group reiterated a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. HC Wainwright raised their target price on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a “buy” rating in a report on Friday, August 7th. TD Cowen lifted their price target on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Finally, Morgan Stanley dropped their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $91.20.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.